Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Attenuated Mumps Vaccine (KMB-17) in Infants
NCT03133923Phase 2Unknown
- Sponsor
- Institute of Medical Biology
- Start
- May 2017
- Primary completion
- Nov 2017
- Modality
- Live Attenuated Vaccines, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised trial of mumps vaccine, live in mumps (3 arms), sponsored by Institute of Medical Biology. Primary endpoints: Positive conversion rate of MuV neutralization antibody at Day 28 and Positive conversion rate of MuV hemagglutination inhibition antibody at Day 28. Status: unknown.
02
Drugs
mumps vaccine, live
03
Conditions
mumps
Beyond the preview
Go deeper on NCT03133923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03133923.